Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis.
Imaging/CT MRI etc
Interstitial Fibrosis
Lung Physiology
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
29
11
2021
accepted:
28
03
2022
entrez:
9
4
2022
pubmed:
10
4
2022
medline:
13
4
2022
Statut:
ppublish
Résumé
Markers of idiopathic pulmonary fibrosis (IPF) severity are based on measurements of forced vital capacity (FVC), diffusing capacity (DLCO) and CT. The pulmonary vessel volume (PVV) is a novel quantitative and independent prognostic structural indicator derived from automated CT analysis. The current prospective cross-sectional study investigated whether respiratory oscillometry provides complementary data to pulmonary function tests (PFTs) and is correlated with PVV. From September 2019 to March 2020, we enrolled 89 patients with IPF diagnosed according to international guidelines. We performed standard spectral (5-37 Hz) and novel intrabreath tracking (10 Hz) oscillometry followed by PFTs. Patients were characterised with the gender-age-physiology (GAP) score. CT images within 6 months of oscillometry were analysed in a subgroup (26 patients) using automated lung texture analysis. Correlations between PFTs, oscillometry and imaging variables were investigated using different regression models. The cohort (29F/60M; age=71.7±7.8 years) had mild IPF (%FVC=70±17, %DLCO=62±17). Spectral oscillometry revealed normal respiratory resistance, low reactance, especially during inspiration at 5 Hz (X5in), elevated reactance area and resonance frequency. Intrabreath oscillometry identified markedly low reactance at end-inspiration (XeI). XeI and X5in strongly correlated with FVC (r XeI is an independent marker of IPF severity that offers additional information to standard PFTs. The data provide a cogent rationale for adding oscillometry in IPF assessment.
Sections du résumé
BACKGROUND
Markers of idiopathic pulmonary fibrosis (IPF) severity are based on measurements of forced vital capacity (FVC), diffusing capacity (DLCO) and CT. The pulmonary vessel volume (PVV) is a novel quantitative and independent prognostic structural indicator derived from automated CT analysis. The current prospective cross-sectional study investigated whether respiratory oscillometry provides complementary data to pulmonary function tests (PFTs) and is correlated with PVV.
METHODS
From September 2019 to March 2020, we enrolled 89 patients with IPF diagnosed according to international guidelines. We performed standard spectral (5-37 Hz) and novel intrabreath tracking (10 Hz) oscillometry followed by PFTs. Patients were characterised with the gender-age-physiology (GAP) score. CT images within 6 months of oscillometry were analysed in a subgroup (26 patients) using automated lung texture analysis. Correlations between PFTs, oscillometry and imaging variables were investigated using different regression models.
FINDINGS
The cohort (29F/60M; age=71.7±7.8 years) had mild IPF (%FVC=70±17, %DLCO=62±17). Spectral oscillometry revealed normal respiratory resistance, low reactance, especially during inspiration at 5 Hz (X5in), elevated reactance area and resonance frequency. Intrabreath oscillometry identified markedly low reactance at end-inspiration (XeI). XeI and X5in strongly correlated with FVC (r
INTERPRETATION
XeI is an independent marker of IPF severity that offers additional information to standard PFTs. The data provide a cogent rationale for adding oscillometry in IPF assessment.
Identifiants
pubmed: 35396320
pii: 9/1/e001163
doi: 10.1136/bmjresp-2021-001163
pmc: PMC8996008
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: C-WC has received speaking fees for webinars supported by Thorasys Thoracic Medical Systems Inc. and has received consulting fees for Theravance Biopharma, Inc. ZH has received consultation fees from Thorasys Thoracic Medical Systems Inc. on subjects unrelated to this study.
Références
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Thorax. 2016 Oct;71(10):907-15
pubmed: 27178219
Respir Med. 2013 Jun;107(6):875-82
pubmed: 23582576
Eur Respir J. 2017 Jan 25;49(1):
pubmed: 27811068
ERJ Open Res. 2020 Dec 14;6(4):
pubmed: 33344627
Eur Respir J. 2019 Sep 30;54(3):
pubmed: 31196945
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1536-1544
pubmed: 32135068
Ann Intern Med. 2012 May 15;156(10):684-91
pubmed: 22586007
Respir Res. 2020 Jan 8;21(1):11
pubmed: 31915023
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Respir Physiol Neurobiol. 2020 Apr;275:103386
pubmed: 31931177
Compr Physiol. 2011 Jul;1(3):1233-72
pubmed: 23733641
Eur Respir J. 2020 Feb 27;55(2):
pubmed: 31772002
Respirology. 2019 May;24(5):445-452
pubmed: 30786325
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232409
Eur Respir J. 2018 Sep 6;52(3):
pubmed: 30190265
Eur Respir J. 2013 Dec;42(6):1513-23
pubmed: 23598954
Respir Care. 2020 Nov;65(11):1687-1693
pubmed: 32209708
Thorax. 2017 Apr;72(4):340-346
pubmed: 27672117
Respir Physiol Neurobiol. 2013 Jan 15;185(2):235-40
pubmed: 23117106
J Thorac Imaging. 2016 Sep;31(5):304-11
pubmed: 27262146
Eur Respir J. 2017 Feb 15;49(2):
pubmed: 28202552
Acad Radiol. 2007 Jul;14(7):772-87
pubmed: 17574128
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232417
J Clin Med. 2020 Nov 23;9(11):
pubmed: 33238466
Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776
pubmed: 29684284
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
ERJ Open Res. 2019 Dec 23;5(4):
pubmed: 31886158